Bladder preservation for MIBC is associated with a higher mortality rate and greater costs compared with radical cystectomy.
Females have worse disease-free, cancer-specific, overall survival versus males with bladder cancer.
Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.
Daily use of aspirin before radical cystectomy is associated with a significant 36% and 30% decreased risk of cancer-specific and all-cause mortality.
In multivariable analyses, CKD stage G3b or higher was significantly associated with worse progression-free and cancer-specific survival.
In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.
The locoregional recurrence-free survival rate at 2 years was significantly higher for patients treated with chemotherapy plus RT versus those treated with chemotherapy alone.
A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.
Mean disease-specific survival at 10 years was 50.9% for TMT and 57.8% for RC patients, a non-significant difference.
Tool incorporates the relative contribution of tumor stage, lymph node involvement.
Radical cystectomy is associated with better survival, but findings suggest BPT may produce acceptable oncologic outcomes in appropriately selected patients.
Researchers find no significant change in overall complication rate from 2010 to 2015, but hospital length of stay and need for transfusion have declined.
Meta-analysis reveals no significant difference in overall-, disease-specific, and progression-free survival between radical cystectomy and radiation-based, bladder preservation therapy.
After recurrent disease, 5-year overall survival was worse among patients with late recurrence.
The researchers found lower overall survival among patients undergoing robot-assisted radical cystectomy at hospitals performing 10 or fewer procedures during 2010 to 2012.
By 2014 to 2015, 1 in 3 bladder cancer surgical procedures performed in the United States were robot-assisted.
Radical cystectomy is associated with better long-term overall survival than trimodal therapy, new study shows.
Finding contrasts with results of randomized clinical trials.
Nomograms specific to radical cystectomy currently do not exist to aid stratification of a patient's risks for complications.
In a study, 53.1% of patients had concomitant prostate cancer in radical cystectomy specimens.
Predictors of distant recurrences after robot-assisted radical cystectomy were mainly dictated by pathological tumor characteristics.
Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.
During first 24 months, 8.7% of patients with favorable pathological characteristics had progressed.
Patients who underwent debulking had significantly longer overall survival compared with those who did not (median 15.7 vs 10 months).
Mortality risk decreases with increasingly stringent BPT compared with radical cystectomy.
Cancer-specific survival at 5 years was 76.9% for men and 71.5% for women.
The timing of office visits and telephone calls helped identify a patient at risk for readmission post-radical cystectomy.
Shorter operating time is one advantage of cutaneous ureterostomy with a single stoma.
The guidelines were assessed for developmental rigor, and the ASCO endorsed all but one of the guidelines.
Current smoking is independently associated with a greater than 2-fold increased odds of hospital readmission after radical cystectomy.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)